BackMirati Therapeutics Overview

Mirati Therapeutics Long Term Debt

Mirati Therapeutics's long-term debt is $42M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$42.20M

Peer trimmed avg / median

Loading

Mirati Therapeutics Long Term Debt History

Loading

Mirati Therapeutics vs. peers: Long Term Debt Comparison

Loading

Mirati Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Mirati Therapeutics (MRTX) FAQ

Mirati Therapeutics (MRTX) currently reports a long-term debt of $42M as of September 2023. In the prior-year period, the figure was $0. Use the charts on this page to explore Mirati Therapeutics's long-term debt history and peer comparisons.

Mirati Therapeutics's long-term debt changed from $0 to $42M (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Mirati Therapeutics reported $42M in long-term debt as of September 2023. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $42M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Mirati Therapeutics, and consider following MRTX for alerts when major investors trade the stock.

Mirati Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $42M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MRTX with unrelated industries.